Skip to content
Search

Latest Stories

WHO rejects tobacco companies' harm reduction claims in a new report

WHO rejects tobacco companies' harm reduction claims in a new report
The WHO condemns tobacco companies' targeting of children through social media and flavored products

The World Health Organization (WHO) reiterated its concerns about tobacco companies' continued targeting of young people through various channels such as social media, sports, and music festivals, as well as the introduction of flavored products.

In a joint report with industry watchdog STOP released on Thursday, the WHO accused these companies of attempting to ensnare a new generation in nicotine addiction.


While facing stricter regulations on traditional cigarettes, major tobacco firms and newcomers have turned to alternatives like vapes, arguing they are intended for adult smokers.

However, the WHO and STOP highlighted in their report that these products often appeal to youth, with their attractive designs and fruity flavors making them more appealing to children than to adults in many countries.

WHO Director-General Tedros Adhanom Ghebreyesus dismissed the industry's claims of harm reduction, asserting that it's misleading to discuss harm reduction while marketing to children.

He stated in the report, "It's dishonest to talk about harm reduction when they are marketing to children."

This stern stance from the WHO comes as youth vaping rates soar globally.

Flavors like bubblegum have been identified as drivers of this trend, although the industry maintains that flavors play a crucial role in persuading adults to transition from smoking.

While large tobacco companies have largely refrained from offering such flavors, the WHO pointed out that firms like Philip Morris International (PMI) and British American Tobacco (BAT) engage in youth-oriented marketing tactics, including sponsoring music and sports events and leveraging social media.

Both PMI and BAT stated their intentions to shift smokers away from cigarettes, with BAT emphasising responsible marketing principles and ensuring products are for adults only.

PMI stressed the importance of scientifically substantiated smoking alternatives and expressed willingness to engage with governments and the WHO on the matter.

Despite these assertions, the WHO highlighted insufficient evidence supporting vapes as smoking cessation aids and pointed out evidence suggesting an increase in traditional cigarette use, particularly among youth, due to vaping.

However, Sarah Jackson from University College London's Tobacco and Alcohol Research Group disputed these claims, stating to Reuters that they do not accurately represent current evidence on e-cigarettes.

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less